Morgan Stanley Stick to Their Buy Rating for Stryker Corporation By Investing.com – Investing.com

Morgan Stanley (NYSE:) analyst Drew Ranieri maintained a Buy rating on Stryker Corporation (NYSE:) on Friday, setting a price target of $305, which is approximately 17.44% above the present share price of $259.7.

Ranieri expects Stryker Corporation to post earnings per share (EPS) of $1.17 for the fourth quarter of 2021.

The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $287.57.The analysts price targets range from a high of $302 to a low of $250.

In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $4.16 billion and a net profit of $590 million. The company's market cap is $97.97 billion.

According to TipRanks.com, Morgan Stanley analyst Drew Ranieri is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.9% and a 40.00% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See the original post here:

Morgan Stanley Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com